Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $17.93 Consensus Target Price from Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $17.93.

Several brokerages have recently weighed in on ROIV. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, November 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th.

Insider Buying and Selling at Roivant Sciences

In related news, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $11.65, for a total value of $1,165,000.00. Following the sale, the chief operating officer now owns 617,470 shares in the company, valued at approximately $7,193,525.50. The trade was a 13.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CIO Mayukh Sukhatme sold 689,495 shares of the firm’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $12.01, for a total value of $8,280,834.95. Following the transaction, the executive now owns 18,836,547 shares of the company’s stock, valued at $226,226,929.47. This trade represents a 3.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,942,629 shares of company stock valued at $23,071,486 over the last quarter. 7.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Roivant Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ROIV. FMR LLC raised its stake in shares of Roivant Sciences by 5.6% in the third quarter. FMR LLC now owns 49,145,056 shares of the company’s stock valued at $567,134,000 after acquiring an additional 2,593,910 shares in the last quarter. Rubric Capital Management LP increased its holdings in Roivant Sciences by 15.0% during the 2nd quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock worth $243,110,000 after purchasing an additional 3,000,000 shares during the period. State Street Corp raised its position in Roivant Sciences by 6.1% in the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company’s stock valued at $225,737,000 after purchasing an additional 1,118,561 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Roivant Sciences by 23.2% in the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock valued at $89,400,000 after buying an additional 1,460,205 shares during the period. Finally, DME Capital Management LP grew its position in shares of Roivant Sciences by 14.8% during the second quarter. DME Capital Management LP now owns 4,810,960 shares of the company’s stock worth $50,852,000 after buying an additional 620,470 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

NASDAQ:ROIV opened at $11.02 on Friday. The stock has a 50 day moving average price of $11.89 and a 200 day moving average price of $11.58. The stock has a market cap of $8.02 billion, a PE ratio of 1.95 and a beta of 1.27. Roivant Sciences has a one year low of $9.69 and a one year high of $13.06.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.